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Mutation of p53 is rare in localized prostate carci-
noma. The oncoprotein MDM2, whose gene has a
response element for p53, promotes the degrada-
tion of p53 protein and inhibits its transcriptional
activation of genes related to cell cycle arrest and
apoptosis, constituting a negative feedback control.
We studied p53 and MDM2 expression by immuno-
histochemistry and looked for mutations in p53 ex-
ons 5 to 8 by polymerase chain reaction-single
strand conformational polymorphism in 118 pa-
tients submitted to radical prostatectomy for local-
ized prostate cancer. In 28 cases, we studied cell
proliferation by immunohistochemistry, using anti-
body for Ki-67, and apoptosis by the deoxynucleo-
tidyl transferase mediated dUTP biotin nick end
labeling technique. Although no p53 mutations
were found, p53 protein was detected in 31.4% of
the cases, and these cases had higher Gleason scores
(P 5 .03) and more advanced tumor stages (P 5 .02).
MDM2 was overexpressed in 40.7% of the cases, and
these cases had greater tumor volumes (P 5 .001).
Tumors that were positive for both p53 and MDM2
were larger (P 5 .003) and of more advanced stage
(P 5 .03). Within the 28-case subset, the prolifera-
tive index was higher among MDM2-positive tu-
mors (P 5 .046), and the apoptotic index was lower
among p53-positive tumors (P 5 .01). We conclude
that, although p53 mutation is a rare event in pros-
tate carcinogenesis, the detection of p53 protein by
immunohistochemistry is common and is associ-
ated with decreased apoptosis and increased histo-
logic grade and tumor stage. We also conclude that
the overexpression of MDM2 has a role in prostate
carcinogenesis, being frequently detected and asso-
ciated with increased cell proliferation and tumor
volume. Finally, we propose that the MDM2-
positive/p53-positive phenotype identifies prostate
cancers with aggressive behavior.
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The p53 protein, which activates genes involved in
cell cycle arrest (1, 2) and apoptosis (3), is missing
or inactive in more than 50% of human tumors as a
result of point mutations or deletions (4, 5) or in-
teractions with proteins (6 – 8). One such protein is
MDM2, a cellular oncoprotein encoded by a gene
located on chromosome 12q13-14 (9). MDM2 binds
to p53, promoting its degradation via ubiquitin,
masking its transactivation domain, and inhibiting
its transcriptional activation of genes related to cell
cycle arrest and apoptosis (9). The transcription of
MDM2 is promoted by p53 (8, 9), creating a nega-
tive feedback control of p53 by MDM2 (9).
Amplification of the MDM2 gene or overexpres-
sion of the MDM2 protein have been implicated in
the development of tumors (8, 10), and MDM2
overexpression has been related to more aggressive
disease and poorer survival. Amplification of
MDM2 has been found in 35% of soft tissue sarco-
mas (11), one third of malignant fibrous histiocyto-
mas (12), 42% of liposarcomas (13), and 7% of os-
teosarcomas (14). Overexpression of MDM2 is
common in lymphoblastic leukemia (15) and bron-
chogenic carcinoma (16), and has been related to
more aggressive disease or poorer survival in these
diseases as well as in lymphoma (17) and bladder
cancer (18). A recent study showed MDM2 overex-
pression in all cases of salivary gland carcinomas,
where p53 mutations are rare (19).
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p53 mutations are also rare in prostate cancer.
They occur only late in the development of the
disease and have been related to metastasis and
androgen-independent growth (20 –22). In one se-
ries, p53 mutations were described in 4.4% of cases
of localized adenocarcinoma, but in 45% of cases of
bone marrow metastasis (20). However, even in the
absence of p53 mutations, it could be that the func-
tion of p53 is abrogated by interactions with an
oncogenic protein such as MDM2. The half-life of
p53 is short, and it is not normally detected by
immunohistochemistry (IHC), but p53 that has
been inactivated by missense mutation or, some-
times, by interaction with other proteins is abnor-
mally stable and, therefore, detectable (9, 23).
The aim of this study was to evaluate the roles
played by p53 mutation, p53 expression, and
MDM2 overexpression in 118 cases of localized
prostatic adenocarcinoma. Mutations of p53 were
detected by polymerase chain reaction-single
strand conformational polymorphism analysis of
exons 5, 6, 7, and 8 (24), and p53 and MDM2 were
detected by IHC. The results were correlated with
the stage, grade, and volume of the tumors. To
further evaluate the roles of p53 and MDM2, cell
proliferation and apoptosis were studied in a subset
of 28 cases selected so that both normal and abnor-
mal expression of p53 and MDM2 would be repre-
sented. A proliferative index was determined by
IHC, using antibody to Ki-67, a protein that is ex-
pressed only by dividing cells (25). An apoptotic
index was determined by the deoxynucleotidyl
transferase mediated dUTP biotin nick end labeling
technique (26).
MATERIALS AND METHODS
Case Selection and Pathologic Examination
One hundred eighteen patients with prostate
cancer, diagnosed by biopsy and clinically staged
T1c-T2, were submitted to radical prostatectomy
between August 1997 and June 1998 at the Hospital
Sirio Libanes of Sao Paulo, Brazil. The surgical spec-
imens were fixed in 10% buffered formalin for no
longer than 4 hours. The entire surgical margin was
stained with India ink, the left and right lobes were
separated, 3-mm transverse serial sections were
taken from each lobe, and the entire gland was
submitted for histologic examination. Sections of
the bladder neck, prostatic apex, seminal vesicles,
and pelvic lymph nodes were also submitted. From
16 to 20 slides of each gland were examined. The
Gleason score was used for histologic grading (27).
The tumor volume was evaluated as described by
Humphrey et al. (28). Briefly, a grid was placed
below the slides, on which the area involved by the
tumor had been previously sketched out. The per-
centage of tumor on a slide was determined by
dividing the number of squares involved by tumor
by the number of squares occupied by the whole
section on the slide. Tumor volume was defined as
the mean percentage of tumor in the prostate gland
(the percentage of tumor on each slide divided by
the number of slides from the prostate gland). Ex-
traprostatic involvement was defined as tumor in-
filtration of the adipose tissue, the neurovascular
plexus, or the parenchyma of the seminal vesicles.
The TNM system was used for tumor staging (29).
p53 Mutation Analysis
DNA Extraction
DNA was extracted from three 10-mm sections of
the paraffin block that best represented each tumor
(previously selected from hematoxylin- and eosin-
stained slides). Disposable microtome blades were
used, and instruments were cleaned with xylene after
each tissue section to avoid cross-contamination.
Three baths in 500 mL of xylene at 95°C followed by
three baths in 500 mL of 99% ethanol were used to
dewax the tissue. Next, the tissue samples were
centrifuged for 5 minutes at 13,000 rpm and 4°C.
The resulting pellets were incubated overnight at
37°C in 500 mL of digestion buffer (10 mM Tris [pH
7.4], 100 mM NaCl, 25 mM disodium EDTA, 0.5%
sodium dodecyl sulfate) containing 10 mL of pro-
teinase K (200mg/mL final concentration). The en-
zyme was inactivated by heating the specimens for
10 minutes at 95°C, protein was removed by adding
an equal volume of phenol:chloroform:isoamyl al-
cohol (25:24:1), and nucleic acid was precipitated
from the aqueous phase by adding ¼ volume 8 M
ammonium acetate and an equal volume of isopro-
panol. The nucleic acid samples were then incu-
bated at 220°C for 1 hour and centrifuged for 10
minutes at 13,000 rpm and 4°C. The resulting pel-
lets were washed in 70% ethanol to remove salt, air
dried, and resuspended in 50 mL of TE/RNAse (30).
Polymerase Chain Reaction Amplification
The polymerase chain reaction (PCR) amplifica-
tion and nonisotopic detection of exons 5 to 8 of the
p53 gene were described by Soong et al. (31) and
will be summarized here. The PCR reactions were
carried out in 25 mL of 1 x Reaction Buffer contain-
ing 0.2 mM deoxynucleotide triphosphates, 2.5 mM
magnesium chloride, each primer at a concentra-
tion of 0.4 mM, 0.25 units of Taq polymerase, and 1
mL of extracted DNA. Thirty-five thermal cycles of
30 seconds at 94°C, 1 minute at 60°C, and 1 minute
at 72°C were completed, and the cycling was con-
cluded by a 10-minute extension at 72°C, all in a
thermocycle Gene Amp PCR System 2400 (Perkin
Elmer, Foster City, CA). All procedures to prevent
contamination were followed.
MDM2 in Prostate Cancer (K.R.M. Leite et al.) 429
SSCP Screening for p53 Mutations
Single-stranded DNA for SSCP analysis was pro-
duced by combining equal 5-mL volumes of PCR
product and formamide loading buffer (95% form-
amide, 10 mM EDTA, 0.05% bromophenol blue,
0.05% xylene cyanol) and heating at 95°C for 10
FIGURE 1. p53 protein expression in prostate adenocarcinoma. StreptABC technique using anti-p53 clone DO7 (original magnification, 2003).
FIGURE 2. Overexpression of MDM2 protein in prostate adenocarcinoma. StreptABC technique using anti-MDM2 clone 1B10 (original
magnification, 2003).
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FIGURE 3. Proliferating cells in prostate adenocarcinoma. StreptABC technique using anti-Ki-67 clone MIB-1 (original magnification, 2003).
FIGURE 4. Apoptotic cells in prostate adenocarcinoma, stained brown by the deoxynucleotidyl transferase mediated dUTP biotin nick end labeling
technique (original magnification, 2003).
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minutes. The DNA was subjected to electrophoresis
at 200 V for 2 hours at 4°C within a Mighty-small
apparatus (Pharmacia, Uppsala, Sweden) contain-
ing a 15% polyacrylamide gel with 5% glycerol. Sil-
ver staining was done by the method of Bassam et
al. (32). The gels were soaked for 5 minutes in 10%
ethanol, 5 minutes in 1% nitric acid, and 10 minutes
in an impregnating solution (0.1 g of silver nitrate
and 150 mL of formaldehyde in 100 mL water); then
soaked in a developing solution (3 g of sodium
carbonate, 150 mL of formaldehyde, and 100 mL of
sodium sulfate in 100 mL water) until bands were
visible; and then fixed in 10% acetic acid for 5
minutes. The gels were analyzed under white light
in a computerized imaging system (Gel Doc 1000,
Biorad, North Ryde, Australia) and compared with
samples of wild-type p53 from normal tissue ex-
tracted and amplified by the same methods to de-
tect p53 mutations, which would appear as extra
bands or mobility shifts.
Immunohistochemical Analysis
Three-micrometer sections from the paraffin
block that best represented the tumor (the same
block used for PCR) were placed on adhesive-
coated slides. In a heat antigen retrieval process
(33) the slides were placed in a citrate buffer (1 mM,
pH 6.0) and heated three times for 8 minutes each
time in a domestic microwave oven at high power.
The slides were incubated overnight at 4°C with
monoclonal antibodies to p53 (clone DO7, Dako,
Glostrup, Denmark), MDM2 (clone 1B10, Novocas-
tra, Newcastle upon Tyne, UK), or Ki-67 (clone
MIB1, Immunotech, Marseille, France) at respec-
tive dilutions of 1:50, 1:50, and 1:100 in phosphate-
buffered saline (PBS). Biotinylated antimouse im-
munoglobulin G was applied at 1:200 dilution for 60
minutes at room temperature. The slides were
rinsed with PBS for 30 minutes, incubated with
peroxidase-conjugated streptavidin (streptABC Kit,
Dako) at 1:400 dilution in PBS for 45 minutes at
room temperature, and then rinsed again with PBS
for 30 minutes. Color was developed by incubating
the slides in 0.06% diaminobenzidine in PBS for 15
minutes, and the slides were then rinsed in tap
water, counterstained with Harris hematoxylin, de-
hydrated, coverslipped, and reviewed under a light
microscope (34). For p53 and MDM2, any dark,
brown nuclear staining was considered positive,
indicating abnormal stabilization of p53 or overex-
pression of MDM2 (Figs. 1 and 2, respectively). For
Ki-67, at least 500 cells were counted, and the per-
centage of cells with dark, brown nuclear staining
(Fig. 3) was considered the proliferative index.
Detection of Apoptosis
The apoptotic index was assessed by the deoxy-
nucleotidyl transferase mediated dUTP biotin nick
end labeling technique using the TDT-FragEL kit
(Oncogene, Cambridge, MA), as described by Gav-
rieli et al. (26). Briefly, 3-mm sections of the paraffin
block that best represented the tumor (the same
block used for PCR and IHC), were placed on
adhesive-coated slides, deparaffinized in xylene,
and rehydrated in alcohol. After cell membranes
were made permeable by treating the slides with
proteinase K diluted 1:10 in 10 mM Tris, pH 8.0, for
20 minutes at room temperature, endogenous per-
oxidase was inactivated by applying 3% H2O2 for 5
minutes at room temperature. Labeling was per-
formed by incubating the slides in a humidified
chamber at 37°C for 1.5 hours with the terminal
deoxynucleotidyl transferase reaction mix from the
kit, which contains labeled and unlabeled de-
oxynucleotides as well as terminal deoxynucleotidyl
transferase enzyme. The reaction was stopped by
applying 0.5 M EDTA, pH 8.0, for 5 minutes at 37°C
and blocked by applying 4% bovine serum albumin
in PBS for 10 minutes at room temperature. The
peroxidase-conjugated streptavidin, diluted 1:50 in
blocking buffer, was applied for 30 minutes at room
temperature in a humidified chamber. The slides
were then incubated with diaminobenzidine, coun-
terstained with methyl green, and coverslipped. At
least 200 cells were counted, and the percentage of
stained cells (Fig. 4) was considered to be the apo-
ptotic index.
Statistical Analysis
To verify significant relationships between vari-
ables, the non-parametric Mann-Whitney and
Kruskal-Wallis tests were used for quantitative vari-
ables, and the x2 test was used for qualitative vari-
ables. P values were two-sided and were considered
significant when less than 0.05. The tests were per-
formed with the computer program SPSS, version 8
(SPSS, Inc., Chicago, IL).
RESULTS
Patient and Tumor Characteristics
The median age of the patients was 63 years
(range, 46 to 75 yr). The median Gleason score was
7 (range, 4 to 10) in the entire study group of 118
patients, and 8 (range, 6 to 10) in the 28-patient
subset for the apoptosis and proliferation studies.
The median tumor volume was 22% (range, 1 to
100; mean, 25.0; SD, 19.4) in the entire group and
26% (range, 1 to 90; mean, 33.2; SD, 24.4) in the
subset for apoptosis and proliferation studies. In
the entire study group, the pathologically deter-
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mined tumor stage was pT2N0 in 69 cases (58.5%),
pT3N0 in 44 cases (37.3%), and pT3N1 in five cases
(4.2%). In the subset for apoptosis and proliferation
studies, the stage was pT2N0 in 17 cases (61%),
pT3N0 in nine cases (32%), and pT3N1 in two cases
(7%).
p53 Mutation
No mutations were detected; electrophoresis of
the amplified products of exons 5, 6, 7, and 8 of the
p53 gene revealed no abnormalities of band migra-
tion in any of the 118 cases studied.
p53 Expression and Grade, Volume, and Stage
of Tumors
Thirty-seven cases (31.4%) were positive for p53.
Among the positive cases, brown staining was
present in a median of 18% of cells. Characteristics
of the p53-positive and p53-negative tumors are
compared in Table 1. Positivity for p53 was related
to the histologic grade of the tumor, with higher
Gleason scores among the p53-positive cases than
among the p53-negative cases. A relationship to
tumor stage also was demonstrated: 23% (16/69) of
the stage pT2 tumors were p53-positive, while 43%
(21/49) of the stage pT3 tumors were p53-positive.
No statistically significant relationship was demon-
strated between p53 and tumor volume.
MDM2 Expression and Grade, Volume, and
Stage of Tumors
MDM2 was overexpressed in 48 patients (40.7%).
In most cases, only the nuclei of tumor cells were
stained; cytoplasmic staining occurred rarely,
mainly in Gleason 4 or 5 patterns. There was no
background staining, and staining was often focal
in the tumor. Characteristics of the MDM2-positive
and MDM2-negative tumors are compared in Table
1. Overexpression of MDM2 was related to tumor
volume: the median volume was 26% for MDM2-
positive tumors and 17% for MDM2-negative tu-
mors. A relationship of borderline significance was
observed between MDM2 and tumor stage: 33%
(23/69) of the stage pT2 tumors were MDM2-
positive, while 51% (25/49) of the stage pT3 tumors
were MDM2-positive. There was no relationship
between MDM2 and the Gleason score.
Interaction of p53 and MDM2 Effects on Grade,
Volume, and Stage of Tumors
When the cases were grouped according to their
expression of both MDM2 and p53 (Table 1), there
were statistically significant differences among the
four groups with respect to tumor volume and tu-
mor stage. The median tumor volume was 38% for
tumors that were positive for both MDM2 and p53,
but only 17% for tumors that were negative for both
proteins. Extraprostatic invasion (stage pT3) was
present in 62% (10/16) of tumors that were positive
for both p53 and MDM2, but only 27% (13/49) of
tumors that were negative for both proteins. Lymph
node status did not appear to be related to p53 or
MDM2 expression. There was no statistically signif-
icant variation in the Gleason score among the four
groups, although the median Gleason score was 8
for tumors that were positive for both p53 and
MDM2 and 6 for those that were negative for both
proteins.
Apoptosis, Cell Proliferation, and p53 or MDM2
Expression
In the subset of 28 cases in which apoptosis and
cell proliferation were studied, the median apopto-
tic index was 3.4% (range, 0.5 to 9.7; mean, 3.8; SD,
2.5), and the median proliferative index was 8%
(range, 0.5 to 23.9; mean, 9.1; SD, 6.2). Table 2
compares the apoptotic and proliferative indexes
for tumors grouped according to their expression of
p53 and MDM2. Positivity for p53 was negatively
associated with the apoptotic index. There was no
statistically significant relationship between p53
and cell proliferation. Overexpression of MDM2
was positively associated with the proliferative in-
dex, but there was no statistically significant rela-
tionship between MDM2 and the apoptotic index.
Interaction of p53 and MDM2 Effects on
Apoptosis and Cell Proliferation
When the cases were grouped according to their
expression of both MDM2 and p53 (Table 2), there
was statistically significant variation among the
four groups in the apoptotic index, with lower in-
dexes occurring in the two p53-positive groups, and
the highest median apoptotic index in the p53-
negative/MDM2-positive group. There was no sta-
tistically significant variation in proliferative index
among the groups, although the median prolifera-
tive index was higher in the two MDM2-positive
groups, with the highest median index in the group
that was positive for both p53 and MDM2.
DISCUSSION
Although we detected no p53 mutations in our
118 cases of localized prostate carcinoma, IHC in-
dicated that p53 was abnormally stabilized in 31%
of the tumors. Among these tumors, the histologic
grade was higher (P 5 .03), the tumor stage was
more advanced (P 5 .02), and the apoptotic index
was lower (P 5 .01) than among the p53-negative
tumors. Overexpression of MDM2 was detected in
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41% of the tumors and was positively related to the
tumor volume (P 5 .001) and the proliferative index
(P 5 .046).
Although the frequency of p53 detection was
somewhat higher in our study than in previous
reports, in which p53 was detected in 5% to 17% of
prostate cancers, our results agreed with these re-
ports that p53 expression is positively related to
tumor stage and tumor grade (20, 22). This relation-
ship of p53 to tumor grade was dramatic in another
series, in which p53 was expressed in only 4.5% of
well-differentiated prostatic carcinomas, but in 80%
of poorly differentiated tumors (35). The frequency
of MDM2 overexpression in our study was similar
to the frequency in other reports that describe
MDM2 overexpression in almost one third to al-
most one half of prostate cancers (36, 37). In a
recent report (37), MDM2 overexpression was re-
lated to tumor stage, a relationship that was of
marginal significance (P 5 .054) in our study.
Our results confirmed other reports that p53 mu-
tations are rare in localized prostate cancer. In sev-
eral studies, p53 mutations were found in only 2%
to 6% of cases (20, 21, 38). A possible explanation
for this low frequency of mutation is that in our
study and most of the other studies with low p53
mutation rates (20, 38, 39), only exons 5 through 8
were examined. When primers to amplify the re-
gion extending from exon 4 through exon 11 were
used to study a series of 48 cases of localized and
metastatic prostate cancer (40), p53 mutations were
found in 77% of the cases, suggesting that exons 4,
9, 10, and 11 ought to be evaluated in addition to
exons 5 through 8.
To interpret our results, it is important to realize
the situations that can cause a tumor to be p53-
positive or p53-negative by IHC. As mentioned be-
fore, p53 normally has too short a half-life to be
detected by IHC (24). Missense mutations are the
most common p53 mutations, and because they
TABLE 1. Characteristics of Tumors Grouped by p53 and MDM2 Expression
Characteristic
Group
p531 p532 MDM21 MDM22 p531/MDM21 p532/MDM21 p531/MDM22 p532/MDM22
Number of cases
(n 5 118)
37 81 48 70 16 32 21 49
Gleason score
Median 7 6 7 6.5 8 6.5 7 6
Range 4 –10 4 –10 4 –10 4 –10 4 –10 4 –10 4 –10 4 –10
Test statistic U 5 1137.5 U 5 1570.5 Kruskal-Wallis x23 5 4.9
P value .03 .54 .18
Tumor volumea
Median (%) 26 19.5 26 17 38.5 23 18 17
Range (%) 1 –90 1 –100 2 –84 1 –100 9 –84 2 –65 1 –90 1 –100
Test statistic U 5 1190.5 U 5 1076.5 Kruskal-Wallis x23 5 14.0
P value .09 .001 .003
Tumor stageb
pT2 16 (43) 53 (65) 23 (48) 46 (66) 6 (38) 17 (53) 10 (48) 36 (73)
pT3 21 (57) 28 (35) 25 (52) 24 (34) 10 (62) 15 (47) 11 (52) 13 (27)
Test statistic x21 5 5.2 x
2
1 5 3.7 x
2
3 5 8.8
P value .02 .054 .03
p531, p53 detected; p532, p53 not detected; MDM21, MDM2 overexpressed; MDM22; MDM2 not overexpressed; U is the Mann-Whitney statistic.
a Tumor volume is percentage of prostate gland infiltrated by tumor.
b Values are number of cases (%). Denominator of percentages is the number of cases in the p53/MDM2 group.
TABLE 2. Apoptotic and Proliferative Indexes of Tumors Grouped by p53 and MDM2 Expression
Index
Group
p531 p532 MDM21 MDM22 p531/MDM21 p532/MDM21 p531/MDM22 p532/MDM22
Number of cases
(n 5 28)
13 15 13 15 5 8 8 7
Apoptotic index
Median (%) 2.4 4.7 4 2.7 2.9 6.7 2.3 3.9
Test statistic U 5 44.000 U 5 62.500 Kruskal-Wallis x23 5 8.5
P value .01 .11 .04
Proliferative index
Median (%) 8.6 7.5 10.6 6.4 15.6 9.3 7.3 6.3
Test statistic U 5 76.000 U 5 54.500 Kruskal-Wallis x23 5 5.6
P value .34 .046 .13
p531, p53 detected; p532, p53 not detected; MDM21, MDM2 overexpressed; MDM22; MDM2 not overexpressed; U is the Mann-Whitney statistic.
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stabilize the p53 protein, they are detected by IHC
(24). Nonsense or frame-shift mutations, gene de-
letions, and mutations that cause truncation of the
protein may not be detected by IHC. The IHC
method can also detect p53 that has been tempo-
rarily stabilized by some mechanism other than
mutation (41), such as the action of the product of
the p19arf gene (42) or the formation of complexes
with proteins such as MDM2 (9, 11). Stabilized p53
that is detected by IHC method is inactive and does
not function normally in the control of the cell cycle
and apoptosis induction (24).
MDM2-positivity by IHC, on the other hand, sig-
nifies that a tumor overexpresses MDM2, whether
as a result of increased transcription (43), enhanced
translation (44), or gene amplification. Amplifica-
tion is the least common of these mechanisms (43,
45); in one prostate carcinoma series (46), no cases
of MDM2 gene amplification were found.
The relationship we found between p53 and ap-
optosis appeared to be partially independent of
MDM2 expression, suggesting that the ability of p53
to induce apoptosis cannot always be abrogated by
MDM2.
The relationship we found between MDM2 over-
expression and cell proliferation was interesting. It
may explain the relationship between MDM2 over-
expression and tumor volume, and it indicates to us
that the overexpression of MDM2 has a role in
prostate carcinogenesis.
Because MDM2 overexpression had a significant
relationship to the proliferative index while p53
positivity did not, it would seem that MDM2 can
affect cell proliferation not only by interfering with
the p53’s control of the cell cycle, but also by some
other mechanism. The cell cycle is negatively con-
trolled by the Rb protein as well as by the p53
protein, and MDM2 may interfere with that control
by interacting with the Rb protein directly (47) or by
inhibiting the ability of transforming growth factor
b to maintain the Rb protein in its active form (48).
Also, a RING finger domain suggests that MDM2
could interact with rRNA, suggesting possible roles
for MDM2 in translation control, RNA transport, or
ribosome biogenesis (8).
Whatever the additional mechanism of MDM2
control over the cell cycle may be, it may add to the
effect of p53 inactivation. In the four-group analy-
sis, the group in which MDM2 and p53 were posi-
tive had a higher median proliferative index than
the other groups, although we were not able to
show this difference to be statistically significant.
This group also had greater tumor volumes (P 5
.003) and more advanced tumor stages (P 5 .03)
than the other groups. It may be that the MDM2-
positive/p53-positive phenotype identifies an ag-
gressive subset of prostate adenocarcinoma. It has
been suggested that the results of IHC investigation
for both proteins, rather than just one, would better
reflect the behavior of tumors (49), and we believe
that assessment of both p53 and MDM2 by IHC
should be part of the evaluation of prostate cancer.
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